These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36839960)

  • 21. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
    Shi F; Su J; Wang J; Liu Z; Wang T
    Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. pH-Responsive STING-Activating DNA Nanovaccines for Cancer Immunotherapy.
    Zhang Y; Shen T; Zhou S; Wang W; Lin S; Zhu G
    Adv Ther (Weinh); 2020 Sep; 3(9):. PubMed ID: 34337143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mn-phenolic networks as synergistic carrier for STING agonists in tumor immunotherapy.
    Meng Y; Huang J; Ding J; Zhou H; Li Y; Zhou W
    Mater Today Bio; 2024 Jun; 26():101018. PubMed ID: 38516172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
    Go EJ; Yang H; Park W; Lee SJ; Han JH; Kong SJ; Lee WS; Han DK; Chon HJ; Kim C
    Small; 2023 Oct; 19(43):e2300544. PubMed ID: 37381624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S-acylthioalkyl ester (SATE)-based prodrugs of deoxyribose cyclic dinucleotides (dCDNs) as the STING agonist for antitumor immunotherapy.
    Xie Z; Lu L; Wang Z; Luo Q; Yang Y; Fang T; Chen Z; Ma D; Quan J; Xi Z
    Eur J Med Chem; 2022 Dec; 243():114796. PubMed ID: 36198216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STING-Activating Small Molecular Therapeutics for Cancer Immunotherapy.
    Huang C; Tong T; Ren L; Wang H
    Chembiochem; 2024 Jul; ():e202400255. PubMed ID: 38980259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity.
    Dane EL; Belessiotis-Richards A; Backlund C; Wang J; Hidaka K; Milling LE; Bhagchandani S; Melo MB; Wu S; Li N; Donahue N; Ni K; Ma L; Okaniwa M; Stevens MM; Alexander-Katz A; Irvine DJ
    Nat Mater; 2022 Jun; 21(6):710-720. PubMed ID: 35606429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
    Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
    Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
    Shen A; Li X; Zhang Y; Ma J; Xiao R; Wang X; Song Z; Liu Z; Geng M; Zhang A; Xie Z; Ding C
    Eur J Med Chem; 2022 Nov; 241():114627. PubMed ID: 35963129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulfonated Perylene as Three-in-One STING Agonist for Cancer Chemo-Immunotherapy.
    Zhao X; Zheng R; Zhang B; Zhao Y; Xue W; Fang Y; Huang Y; Yin M
    Angew Chem Int Ed Engl; 2024 Mar; 63(11):e202318799. PubMed ID: 38230819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnitude of Therapeutic STING Activation Determines CD8
    Sivick KE; Desbien AL; Glickman LH; Reiner GL; Corrales L; Surh NH; Hudson TE; Vu UT; Francica BJ; Banda T; Katibah GE; Kanne DB; Leong JJ; Metchette K; Bruml JR; Ndubaku CO; McKenna JM; Feng Y; Zheng L; Bender SL; Cho CY; Leong ML; van Elsas A; Dubensky TW; McWhirter SM
    Cell Rep; 2018 Dec; 25(11):3074-3085.e5. PubMed ID: 30540940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy.
    Doshi AS; Cantin S; Prickett LB; Mele DA; Amiji M
    J Control Release; 2022 May; 345():721-733. PubMed ID: 35378213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming STING Agonists Barriers: Peptide, Protein, and Biomembrane-based Biocompatible Delivery Strategies.
    Zheng YF; Wu JJ
    Chem Asian J; 2022 Mar; 17(6):e202101400. PubMed ID: 35080118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
    Meric-Bernstam F; Sweis RF; Hodi FS; Messersmith WA; Andtbacka RHI; Ingham M; Lewis N; Chen X; Pelletier M; Chen X; Wu J; Dubensky TW; McWhirter SM; Müller T; Nair N; Luke JJ
    Clin Cancer Res; 2023 Jun; 29(12):2336. PubMed ID: 37309603
    [No Abstract]   [Full Text] [Related]  

  • 35. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
    Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation.
    Zhang BD; Wu JJ; Li WH; Hu HG; Zhao L; He PY; Zhao YF; Li YM
    Nano Res; 2022; 15(7):6328-6339. PubMed ID: 35464625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
    Xie X; Liu J; Wang X
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDE-stable 2'3'-cGAMP analogues, containing 5'-S-phosphorothioester linkage, as STING agonists.
    Yeboah SK; Sintim HO
    RSC Med Chem; 2024 May; 15(5):1508-1514. PubMed ID: 38784462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
    Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
    Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models.
    Takahashi-Ruiz L; Fermaintt CS; Wilkinson NJ; Chan PYW; Mooberry SL; Risinger AL
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.